-$1.80 Earnings Per Share Expected for Esperion Therapeutics Inc (ESPR) This Quarter
Equities analysts expect Esperion Therapeutics Inc (NASDAQ:ESPR) to announce ($1.80) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Esperion Therapeutics’ earnings, with the lowest EPS estimate coming in at ($2.05) and the highest estimate coming in at ($1.47). Esperion Therapeutics reported earnings of ($1.29) per share during the same quarter last year, which would indicate a negative year over year growth rate of 39.5%. The firm is expected to announce its next quarterly earnings results on Wednesday, February 28th.
On average, analysts expect that Esperion Therapeutics will report full year earnings of ($7.30) per share for the current financial year, with EPS estimates ranging from ($7.63) to ($6.90). For the next year, analysts expect that the company will report earnings of ($6.39) per share, with EPS estimates ranging from ($8.54) to ($4.65). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Esperion Therapeutics.
A number of equities analysts have commented on ESPR shares. UBS Group set a $88.00 target price on shares of Esperion Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 17th. BidaskClub upgraded shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 13th. Chardan Capital increased their price objective on shares of Esperion Therapeutics from $20.00 to $75.00 and gave the company a “neutral” rating in a research note on Wednesday, December 6th. Credit Suisse Group started coverage on shares of Esperion Therapeutics in a research note on Wednesday, January 17th. They set an “outperform” rating and a $103.00 price objective on the stock. Finally, Needham & Company LLC upgraded shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and increased their price objective for the company from $72.00 to $81.00 in a research note on Thursday, December 14th. Six analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Esperion Therapeutics has a consensus rating of “Buy” and an average target price of $77.23.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ESPR. Tower Research Capital LLC TRC lifted its position in Esperion Therapeutics by 69,371.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock valued at $225,000 after acquiring an additional 4,856 shares during the last quarter. First Mercantile Trust Co. lifted its position in Esperion Therapeutics by 56.0% during the fourth quarter. First Mercantile Trust Co. now owns 4,233 shares of the biopharmaceutical company’s stock valued at $279,000 after acquiring an additional 1,519 shares during the last quarter. Creative Planning purchased a new stake in Esperion Therapeutics during the fourth quarter valued at approximately $314,000. Oakmont Partners LLC purchased a new stake in Esperion Therapeutics during the fourth quarter valued at approximately $323,000. Finally, Voya Investment Management LLC lifted its position in Esperion Therapeutics by 12.7% during the second quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock valued at $331,000 after acquiring an additional 806 shares during the last quarter. Hedge funds and other institutional investors own 92.85% of the company’s stock.
Esperion Therapeutics (NASDAQ ESPR) opened at $65.94 on Tuesday. The company has a market cap of $1,690.00, a PE ratio of -9.61 and a beta of 2.64. Esperion Therapeutics has a one year low of $13.41 and a one year high of $82.18.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.